TY - JOUR
T1 - Peer education for secondary stroke prevention in inner-city minorities
T2 - Design and methods of the prevent recurrence of all inner-city strokes through education randomized controlled trial
AU - Goldfinger, Judith Z.
AU - Kronish, Ian M.
AU - Fei, Kezhen
AU - Graciani, Albert
AU - Rosenfeld, Peri
AU - Lorig, Kate
AU - Horowitz, Carol R.
PY - 2012/9
Y1 - 2012/9
N2 - Background: The highest risk for stroke is among survivors of strokes or transient ischemic attacks (TIA). However, use of proven-effective cardiovascular medications to control stroke risk is suboptimal, particularly among the Black and Latino populations disproportionately impacted by stroke. Methods: A partnership of Harlem and Bronx community representatives, stroke survivors, researchers, clinicians, outreach workers and patient educators used community-based participatory research to conceive and develop the Prevent Recurrence of All Inner-city Strokes through Education (PRAISE) trial. Using data from focus groups with stroke survivors, they tailored a peer-led, community-based chronic disease self-management program to address stroke risk factors. PRAISE will test, in a randomized controlled trial, whether this stroke education intervention improves blood pressure control and a composite outcome of blood pressure control, lipid control, and use of antithrombotic medications. Results: Of the 582 survivors of stroke and TIA enrolled thus far, 81% are Black or Latino and 56% have an annual income less than $15,000. Many (33%) do not have blood pressures in the target range, and most (66%) do not have control of all three major stroke risk factors. Conclusions: Rates of stroke recurrence risk factors remain suboptimal in the high risk, urban, predominantly minority communities studied. With a community-partnered approach, PRAISE has recruited a large number of stroke and TIA survivors to date, and may prove successful in engaging those at highest risk for stroke and reducing disparities in stroke outcomes in inner-city communities.
AB - Background: The highest risk for stroke is among survivors of strokes or transient ischemic attacks (TIA). However, use of proven-effective cardiovascular medications to control stroke risk is suboptimal, particularly among the Black and Latino populations disproportionately impacted by stroke. Methods: A partnership of Harlem and Bronx community representatives, stroke survivors, researchers, clinicians, outreach workers and patient educators used community-based participatory research to conceive and develop the Prevent Recurrence of All Inner-city Strokes through Education (PRAISE) trial. Using data from focus groups with stroke survivors, they tailored a peer-led, community-based chronic disease self-management program to address stroke risk factors. PRAISE will test, in a randomized controlled trial, whether this stroke education intervention improves blood pressure control and a composite outcome of blood pressure control, lipid control, and use of antithrombotic medications. Results: Of the 582 survivors of stroke and TIA enrolled thus far, 81% are Black or Latino and 56% have an annual income less than $15,000. Many (33%) do not have blood pressures in the target range, and most (66%) do not have control of all three major stroke risk factors. Conclusions: Rates of stroke recurrence risk factors remain suboptimal in the high risk, urban, predominantly minority communities studied. With a community-partnered approach, PRAISE has recruited a large number of stroke and TIA survivors to date, and may prove successful in engaging those at highest risk for stroke and reducing disparities in stroke outcomes in inner-city communities.
KW - Clinical trial
KW - Community-based participatory research
KW - Disparities
KW - Peer education
KW - Stroke
KW - Transient ischemic attack
UR - http://www.scopus.com/inward/record.url?scp=84864293328&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2012.06.003
DO - 10.1016/j.cct.2012.06.003
M3 - Article
C2 - 22710563
AN - SCOPUS:84864293328
SN - 1551-7144
VL - 33
SP - 1065
EP - 1073
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
IS - 5
ER -